

Preclinical Comparison of Two Hypomethylating Nucleosides in Tumor-Bearing Dogs

This clinical trial led by the National Cancer Institute (NCI) assesses the safety and effectiveness of TdCyd and Aza-TdC, novel anticancer agents, when given to dogs with cancer. Studies in dogs with cancer will complement currently open human trials designed to test new doses and effects of these agents.

What qualifies my pet?

- Body weight of ≥ 15 kg
- Histologically confirmed lymphoma or solid tumor accessible for repeated biopsy
- Lymphoma may be confirmed by pre-treatment biopsy or cytology
- Favorable performance status (grade 0/1)
- No significant other health problems
- Dogs must be off all chemotherapy (except L-asparaginase) and radiation therapy for 2 weeks prior to study enrollment
- Both newly diagnosed dogs and those with recurrent/relapsed disease are eligible

Client compensation

Most costs associated with this study will be covered as part of your participation. The management of any complications arising from study drug administration will be covered by study funds up to \$1,250/per dog/event.

**Learn more
and pre-screen here:**

